TNFRSF4 and melanoma: Concretely, clinical trials of OX40 agonist antibody drugs, such as MOXR09016, dacetuzumab, CP-870, CP-893, and Chi Lob 7/4, have been planned and started for non-small cell lung cancer, squamous cell carcinoma of the head and neck, malignant melanoma, triple-negative breast cancer, and colorectal cancer [32,33].